Pharmacology Flashcards

(37 cards)

1
Q

describe the structure of the alpha motor neurone

A

it is myelinated

cell bodies are located in the spinal cord and brainstem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what happens to the alpha motor neurone as it nears the muscle?

A

it divides into unmyelinated branches which end in a terminal bouton (NMJ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

synaptic vesicles containing ACh in the NMJ are located where?

A

active zones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

where are nAChR located?

A

junctional folds that face active zones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

pre-synaptic processes

A
  • choline is transported into the terminal by choline transporter (symport with Na+)
  • ACh is synthesised in the cytosol with acetyl coenzyme A by choline acetyltransferase
  • ACh is concentrated in vesicles by vesicular ACh transporter
  • AP causes depolarisation and Ca2+ enters and causes vesicles in active zones to undergo exocytosis
  • ACh diffuses into the synaptic cleft and activates nAChR in endplate region
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

post-synaptic processes

A
  • two ACh molecules activate each nAChR (pentamers of glycoprotein subunits surrounding central cation pore with a gate that only opens when ACh binds)
  • channel is equally permeable to Na+ and K+, but does not conduct anions
  • when the gate is open Na+ influxes at a faster rate than K+ effluxes
  • causes simultaneous opening of many nAChR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what terminates ACh

A

hydrolysis by acetylcholinesterase (enzymes associated with the endplate membrane).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

five examples of the clinical relevance of the NMJ

A
neuromyotonia 
Lambert-Eaton Myasthenia Syndrome
Myasthenia gravis
botulinum toxin
curare-like compounds
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe neuromyotonia

A

autoantibodies to K+ channels leading to excitability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

presentation of neuromyotonia

A

cramps
stiffness
slow relaxation
twitches

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

management of neuromyotonia

A

carbamazepine and phenytoin block Na+ channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe Lambert-Eaton myasthenic syndrome

A

autoantibodies to Ca2+ channels leading to reduced Ca2+ entry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

presentation of LEMS (small cell lung carcinoma association)

A

muscle weakness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

management of LEMS

A

anticholinesterases e.g. pyridostigmine

K+ channel blockers e.g. 3,4-diaminopyridine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

describe myasthenia gravis

A

progressive muscle weakness during periods of activity, eye and eyelids

autoantibodies against nAChR in endplate region reducing functional challenges and AP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

management of myasthenia gravis

A

anticholinesterases e.g. edrophonium

immunosuppressants e.g. azathioprine

17
Q

describe botulinum toxin

A

exotoxin that irreversibly inhibits ACh release. it modifies proteins involved in vesicles preventing exocytosis (used in botox)

18
Q

role of curare-like compounds (muscle relaxant)

A

competitive antagonist of ACh

19
Q

three classes of drugs involved in inflammatory arthritis management

A
  • NSAIDs
  • DMARDs
  • biologics
20
Q

examples of NSAIDs used in inflammatory arthritis management

A

ibuprofen
naproxen
diclofenac

21
Q

describe NSAIDs

A

anti-inflammatory with analgesic properties

22
Q

indications for NSAIDs

A

inflammatory arthritis
mechanical MSK pain
pleuritic/pericardial pain

23
Q

adverse of NSAIDs

A

peptic ulceration

increased risk of cardiovascular problems

24
Q

when should DMARDs be started in inflammatory arthritis?

A
within 3 months of symptom onset
slow onset (weeks-months)
25
examples of DMARDs
- methotrexate - leflunomide - sulfasalazine - hydroxycholorquine - others e.g. sodium aurothiomalate and penicillamine
26
what is methotrexate used in?
RA psoriatic arthritis CT disease vasculitis
27
adverse of methotrexate
``` leukopenia thrombocytopenia cirrhosis pneumonitis rash/mouth ulcers nausea diarrhoea teratogenic- stop 3 months before conception need FBC and LFTs monitoring ```
28
what is often used in combination with methotrexate?
sulfasalazine
29
adverse of sulfasalazine
``` nausea mouth ulcers low sperm count hepatitis monitoring of FBC and LFTs required ```
30
what is hydroxychloroquine used in?
all connective tissue diseases
31
describe biologics
they are drugs designed to target specific aspects of the immune system
32
what scoring system is used to determine the need for biologics?
DAS28
33
examples of biologics
anti-TNF e.g. infliximab, adalimumab, etanercept rituximab (B cells) tocilizumab (IL-6) secukinimab (IL-17)
34
when is anti-TNF used?
RA psoriatic arthritis ankylosing spondylitis
35
adverse of anti-TNF
risk of infection (TB) malignancy (skin) contradicted in pulmonary fibrosis and HF
36
acute management of gout
colchicine (diarrhoea) NSAIDs steroids
37
prophylaxis of gout
allopurinol (xanthine oxidase inhibitor reducing uric acid levels) febuxostat (used in those who cannot tolerate allopurinol) uricosurics